Image

An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks

An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks

Recruiting
30-85 years
All
Phase N/A

Powered by AI

Overview

Driving ability in older adults is essential for independent mobility and social participation, yet declines under high cognitive load or distraction often lead to visual attention failures such as "look-but-fail-to-see," increasing crash risk. Older adults and individuals with mild cognitive impairment (MCI) show impairments in visual attention, executive control, and visuomotor integration, which are not adequately captured by conventional assessments. Virtual reality (VR) integrated with eye-tracking and upper-limb motion analysis enables ecologically valid simulation of driving scenarios and precise quantification of visuomotor behavior. However, current studies are limited by single-scenario designs, unimodal AI models, and insufficient integration of action-related data.

This study proposes a multi-phase framework: Year 1 develops an eye-movement-based AI model for MCI identification; Year 2 integrates multimodal data in VR driving tasks; and Year 3 establishes an explainable AI system with longitudinal validation. The study aims to advance cognitive assessment and develop a digital tool for early MCI detection and driving risk prediction.

Description

Driving ability in older adults is closely associated with independent mobility and social participation. However, under conditions of high cognitive load or distraction, visual attention failures-such as the "look-but-fail-to-see" phenomenon-frequently occur and substantially increase crash risk. Previous studies have demonstrated that older adults and individuals with mild cognitive impairment (MCI) exhibit declines in visual attention allocation, executive control, and visuomotor transformation efficiency. These dynamic regulatory processes are difficult to capture using conventional paper-and-pencil or static neuropsychological assessments, underscoring the need for ecologically valid and dynamic evaluation approaches.

Virtual reality (VR), when integrated with eye-tracking and upper-limb motion analysis, enables the simulation of realistic driving environments under safe and controlled conditions. This approach facilitates precise quantification of visual search behavior, hazard detection, and visuomotor coupling, thereby offering a novel framework for cognitive assessment and driving risk prediction. Despite these advances, three critical gaps remain in the current literature: (1) a lack of systematic investigations focusing on older adults and individuals with MCI across diverse VR driving scenarios to examine visual search and attentional control; (2) artificial intelligence (AI) models that are predominantly limited to single tasks or single modalities, restricting their ability to generalize across contexts; and (3) insufficient integration of upper-limb operational data to fully characterize the dynamic interactions among vision, action, and cognition.

To address these gaps, this study adopts a multi-phase, multi-level research design. In Year 1, a VR-based eye-movement system incorporating controllable cognitive load will be developed to examine pro-saccade and anti-saccade performance among young adults, cognitively healthy older adults, and individuals with MCI. This phase will establish a high-sensitivity, eye-movement-based AI model for MCI identification. In Year 2, the framework will be extended to multi-scenario VR driving tasks through the synchronous integration of eye-tracking and upper-limb operational data, enabling characterization of visuomotor coupling under varying cognitive demands. External validation, transfer learning, and multimodal fusion techniques will be applied to enhance cross-scenario generalizability. In Year 3, multimodal datasets will be integrated to develop an explainable artificial intelligence (XAI) prediction system. Longitudinal follow-up will be conducted to evaluate its prognostic validity for changes in cognitive and driving performance, ultimately leading to a clinically applicable decision-support prototype.

At the theoretical level, this study aims to elucidate the mechanisms underlying visual attention, working memory, executive control, and visuomotor coupling in older adults and individuals with MCI under dynamic conditions. At the clinical and practical levels, it seeks to develop a non-invasive and repeatable digital cognitive screening tool for early MCI detection and older-driver risk assessment, as well as to provide evidence-based support for traffic safety policy development.

Eligibility

Inclusion Criteria:

  1. A score of 23 or higher on the Montreal Cognitive Assessment.
  2. A Clinical Dementia Rating score of 0 for cognitively healthy participants or 0.5 for participants with mild cognitive impairment (MCI).
  3. Age between 30 and 39 years for healthy young adults, or between 65 and 85 years for cognitively healthy older adults and participants with MCI.
  4. Right-hand dominance.
  5. Adequate visual function to complete virtual reality (VR) and eye-tracking tasks, defined as corrected binocular visual acuity of at least 0.5 without severe visual field deficits.

Exclusion Criteria:

  1. Presence or history of major psychiatric disorders or central nervous system diseases.
  2. Significant ocular diseases, such as untreated cataracts, active retinal diseases, moderate-to-severe or poorly controlled glaucoma, or marked visual field deficits beyond a specified level.
  3. Epilepsy.
  4. Severe dizziness or VR-induced motion sickness.

Study details
    Mild Cognitive Impairment (MCI)
    Virtual Reality
    Eye Movement Disorder
    Multimodal Monitoring
    Older Adults

NCT07656389

National Cheng-Kung University Hospital

14 November 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.